Trial Profile
A 12-Week, Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Parallel Group Study to Evaluate the Safety, Tolerability and Efficacy Of Once Daily PF-04971729 And Sitagliptin On Glycemic Control And Body Weight In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Ertugliflozin (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 16 Sep 2011 Results presented at the 47th Annual Meeting of the European Association for the Study of Diabetes.
- 14 Mar 2011 Planned end date changed from 1 Jan 2011 to 1 Dec 2010 as reported by ClinicalTrials.gov.
- 01 Jan 2011 Status changed from recruiting to completed.